CTA
NTLA icon

Colonial Trust Advisors’s Intellia Therapeutics NTLA Stock Holding History

Colonial Trust Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$846 Hold
50
– – ﹤0.01% 760
2026
Q1 		$641 Hold
50
– – ﹤0.01% 690
2025
Q4 		$450 Hold
50
– – ﹤0.01% 671
2025
Q3 		$864 Hold
50
– – ﹤0.01% 645
2025
Q2 		$469 Hold
50
– – ﹤0.01% 668
2025
Q1 		$356 Hold
50
– – ﹤0.01% 651
2024
Q4 		$583 Hold
50
– – ﹤0.01% 647
2024
Q3 		$1.03K Sell
50
-50
-50% -$1.15K ﹤0.01% 709
2024
Q2 		$2.24K Buy
100
+25
+33% +$595 ﹤0.01% 673
2024
Q1 		$2.06K Hold
75
– – ﹤0.01% 801
2023
Q4 		$2.29K Hold
75
– – ﹤0.01% 697
2023
Q3 		$2.37K Hold
75
– – ﹤0.01% 701
2023
Q2 		$3.06K Hold
75
– – ﹤0.01% 694
2023
Q1 		$2.79K Buy
75
+25
+50% +$981 ﹤0.01% 690
2022
Q4 		$1.75K Buy
+50
New +$2.38K ﹤0.01% 742

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Colonial Trust Advisors's NTLA Position: Q2 2026 in Review

Colonial Trust Advisors held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 50 shares worth $846. The position accounts for ﹤0.01% of the portfolio, ranked #760.

Colonial Trust Advisors first reported a position in NTLA in Q4 2022 and has held it in 15 quarters since. The position peaked at $3.06K in Q2 2023. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Colonial Trust Advisors held 50 shares of Intellia Therapeutics worth $846 as of Q2 2026.
  • Colonial Trust Advisors left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Colonial Trust Advisors's portfolio in Q2 2026, its #760 holding.
  • Colonial Trust Advisors first reported a position in Intellia Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Colonial Trust Advisors's Intellia Therapeutics position peaked at $3.06K in Q2 2023.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Colonial Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.